文献速递心力衰竭与心肌病

沙库巴曲/缬沙坦对射血分数保留的心力衰竭患者认知功能的影响:PARAGON-HF预设分析

Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
PubMed 文献 · Circulation · 2024-06-06

本研究为PARAGON-HF预设亚组分析,纳入2895例射血分数保留的心力衰竭患者,比较沙库巴曲/缬沙坦与缬沙坦对认知功能(MMSE评分)的影响。中位随访32个月,96周时两组MMSE评分变化无差异(均差-0.01,95%CI -0.20至0.19,P=0.95),认知下降、认知障碍及痴呆相关不良事件亦无差异。

要点

  • 沙库巴曲/缬沙坦不增加HFpEF患者认知功能下降风险。
  • 96周MMSE评分变化两组无显著差异(P=0.95)。
  • 认知下降、痴呆相关不良事件等次要终点亦无差异。

核心结论

  • 在HFpEF患者中,沙库巴曲/缬沙坦与缬沙坦相比未显著影响认知功能变化。

研究设计与样本

  • PARAGON-HF预设亚组分析,纳入2895例HFpEF患者,随机分配至沙库巴曲/缬沙坦组(1453例)或缬沙坦组(1442例),中位随访32个月。

主要发现

  • 96周时MMSE评分变化组间均差-0.01(95%CI -0.20至0.19;P=0.95)。
  • MMSE下降≥3分、评分<24、痴呆相关不良事件及其组合分析均无组间差异。
  • 载脂蛋白E ε4等位基因亚组分析亦未发现差异。

关键数值与推荐

  • 基线平均MMSE评分27.4±3.0(沙库巴曲/缬沙坦组),10%患者MMSE<24。
  • 主要终点为96周MMSE评分较基线变化。
  • 认知下降定义为MMSE评分下降≥3分;认知障碍定义为MMSE评分<24。

临床怎么用

  • 对于HFpEF患者,使用沙库巴曲/缬沙坦时无需过度担忧认知功能恶化。

局限性

  • 本研究为预设亚组分析,样本量有限,认知功能评估采用MMSE,敏感性可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer-type dementia. To address this, we examined the effect of sacubitril/valsartan compared with valsartan on cognitive function in patients with heart failure with preserved ejection fraction in a prespecified substudy of PARAGON-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). METHODS: In PARAGON-HF, serial assessment of cognitive function was conducted in a subset of patients with the Mini-Mental State Examination (MMSE; score range, 0-30, with lower scores reflecting worse cognitive function). The prespecified primary analysis of this substudy was the change from baseline in MMSE score at 96 weeks. Other post hoc analyses included cognitive decline (fall in MMSE score of ≥3 points), cognitive impairment (MMSE score <24), or the occurrence of dementia-related adverse events. RESULTS: Among 2895 patients included in the MMSE substudy with baseline MMSE score measured, 1453 patients were assigned to sacubitril/valsartan and 1442 to valsartan. Their mean age was 73 years, and the median follow-up was 32 months. The mean±SD MMSE score at randomization was 27.4±3.0 in the sacubitril/valsartan group, with 10% having an MMSE score <24; the corresponding numbers were nearly identical in the valsartan group. The mean change from baseline to 96 weeks in the sacubitril/valsartan group was -0.05 (SE, 0.07); the corresponding change in the valsartan group was -0.04 (0.07). The mean between-treatment difference at week 96 was -0.01 (95% CI, -0.20 to 0.19; P=0.95). Analyses of a ≥3-point decline in MMSE, decrease to a score <24, dementia-related adverse events, and combinations of these showed no difference between sacubitril/valsartan and valsartan. No difference was found in the subgroup of patients tested for apolipoprotein E ε4 allele genotype. CONCLUSIONS: Patients with heart failure with preserved ejection fraction in PARAGON-HF had relatively low baseline MMSE scores. Cognitive change, measured by MMSE, did not differ between treatment with sacubitril/valsartan and treatment with valsartan in patients with heart failure with preserved ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Dewan, Shen, Pedro Ferreira, et al. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF. Circulation. 2024. PMID: 38841854. doi:10.1161/CIRCULATIONAHA.124.068774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。